07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

AP301: Phase IIa data

Top-line data from a double-blind, Austrian Phase IIa trial in mechanically-ventilated ARDS patients showed that orally inhaled AP301 led to earlier onset and "more pronounced activation" of pulmonary edema clearance vs. placebo. Additionally, a subgroup...
00:05 , Apr 10, 2014 |  BC Extra  |  Clinical News

Apeptico reports Phase II data for pulmonary product

Apeptico Forschung und Entwicklung GmbH (Vienna, Austria) said orally inhaled AP301 led to earlier onset and "more pronounced activation" of pulmonary edema clearance vs. placebo in a Phase IIa trial to treat pulmonary permeability edema...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Company News

Apeptico, Chem Tech Research Ltd. (C-TRI) deal

Apeptico granted C-TRI a non-exclusive license to Apeptico's Pepbase database of human therapeutic proteins. The database includes proteins that are manufactured with recombinant DNA technology and are approved in the EU or U.S. Pepbase's profile...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

AP301: Phase IIa start

Next month, Apeptico will begin a placebo-controlled, Austrian Phase IIa trial to evaluate AP301 delivered via aerosol by nebulizer technology for up to 7 days in mechanically ventilated patients with primary graft dysfunction following lung...
08:00 , Jan 28, 2013 |  BC Week In Review  |  Clinical News

AP301 regulatory update

Apeptico said FDA and EMA granted Orphan Drug designation to AP301 to treat high altitude pulmonary edema. The product is in Phase IIa testing to treat edematous respiratory failure. AP301 also has Orphan Drug designation...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Clinical News

AP301: Phase II started

Apeptico began a double-blind, placebo-controlled, Austrian Phase II trial to evaluate 87.6 mg AP301 delivered via aerosol by nebulizer technology every 12 hours for up to 7 days in about 40 patients with pulmonary edema....
07:00 , May 28, 2012 |  BC Week In Review  |  Financial News

Apeptico completes venture financing

Apeptico Forschung und Entwicklung GmbH , Vienna, Austria   Business: Pulmonary   Date completed: 5/16/12   Type: Venture financing   Raised: €2 million ($2.6 million)   Investors: BioScience Ventures Group; V+ GmbH & Co. Fonds...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Clinical News

AP301: Phase I data

A double-blind, placebo-controlled, dose-escalation, Austrian Phase I trial in 48 healthy volunteers showed that single doses of 4-120 mg AP301 delivered via aerosol by nebulizer technology were well tolerated with no serious adverse side effects...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Clinical News

AP301: Phase I started

Apeptico began a double-blind, placebo-controlled, dose-escalation, Austrian Phase I trial to evaluate a single dose of AP301 delivered via aerosol by nebulizer technology in up to 48 patients with lung infection, lung injury or lung...
07:00 , Aug 16, 2010 |  BC Week In Review  |  Financial News

Apeptico completes venture financing

Apeptico Forschung und Entwicklung GmbH , Vienna, Austria   Business: Pulmonary   Date completed: 8/5/10   Type: Venture financing   Raised: €3 million ($3.9 million)   Investors: BioScience Ventures Group; V+ GmbH & Co. Fonds...